Abstract
The ability of a novel permeation enhancer, sodium tauro-24,25-dihydrofusidate (STDHF), to increase the systemic delivery of human growth hormone (hGH); after intranasal administration was investigated in rat, rabbit, and sheep. Formulations of hGH with STDHF exhibited greatly enhanced nasal absorption at concentrations of STDHF above its critical micelle concentration. The increase in bioavailability was 11-fold in rats and in rabbits and 21-fold in sheep for formulations containing 0.5% STDHF as compared to those without STDHF. Glycocholate or taurocholate at 0.5% was three to five times less effective than STDHF at enhancing hGH absorption in rats. Additionally, the pulsatile absorption kinetics observed after intranasal delivery more closely resemble the endogenous secretory pattern of hGH than those obtained following subcutaneous administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
V. H. L. Lee. Pharm. Int. 7:208–212 (1986).
A. S. Harris. In S. S. Davis, L. Illum, and E. Tomlinson (eds.), Delivery Systems for Peptide Drugs, Plenum Press, New York, 1986, pp. 191–204.
W. A. Lee and J. P. Longenecker. BioPharm 1:30–37 (1988).
M. C. Carey, A. C. Moses, and J. S. Flier. U.S. Patent 4 548 922 (1985).
J. P. Longenecker, A. C. Moses, J. S. Flier, R. D. Silver, M. C. Carey, and E. J. Dubovi. J. Pharm. Sci. 76:351–355 (1987).
M. S. Nolte, C. Taboga, E. Salamon, L. Silveira, A. Moses, P. H. Forsham, and J. H. Karam. Proc. 47th Sci Sess. Mtg., American Diabetes Association, June 7–9, 1987.
L. Russo and W. V. Moore. J. Clin. Endocrinol. Metabol. 55:1003–1006 (1982).
K. Albertsson-Wikland, O. Westphal, and U. Westgren. Acta Paediat. Scand. 75:89–97 (1986).
S. D. Frasier. Endocrine Rev. 4:155–170 (1983).
K. W. Kastrup, J. Sandahl-Christiansen, J. Koch-Andersen, and H. Orskov. Acta Endocrinol. 104:148–152 (1983).
M. Hermanussen, K. Geiger-Benoit, and W. G. Sippell. Acta Endocrinol. 109:163–168 (1985).
A. L. Daugherty, H. D. Liggitt, J. G. McCabe, J. A. Moore, and J. S. Patton. Int. J. Pharm. 45:197–206 (1988).
J. S. Friedman, C. L. Cofer, C. L. Anderson, J. A. Kushner, P. P. Gray, G. E. Chapman, M. C. Stuart, L. Lazarus, J. Shine, and P. J. Kushner. Bio/technology 7:359–362 (1989).
H. Salem. Arch. Otolaryn. 96:524–529 (1972).
S. Hirai, Y. Yakatsuka, T. Matsuzawa, and H. Mima. Int. J. Pharm. 7:165–172 (1981).
S. Hirai, T. Yashiki, and H. Mima. Int. J. Pharm. 9:173–184 (1981).
J. A. Moore, H. Wilking, and A. L. Daugherty. In S. S. Davis, L. Illum, and E. Tomlinson (eds.), Delivery Systems for Peptide Drugs, Plenum Press, New York, 1986, pp. 317–330.
S. T. Anik, G. McRae, C. Nerenberg, A. Worden, J. Foreman, J. Hwang, S. Kushinsky, R. Jones, and B. Vickery. J. Pharm. Sci. 73:684–685 (1984).
M. C. Carey and D. M. Small. Biochim. Biophys. Acta 306:51–57 (1973).
M. C. Carey and D. M. Small. J. Lipid Res. 12:604–613 (1971).
R. D. Ennis, L. Borden, C. Grimm, and P. A. Baldwin. J. Electron Microsc. Techn. 7:133 (1987).
R. D. Ennis, L. Borden, and W. A. Lee. Pharm. Res. 7:468–475 (1990).
G. S. Gordon, A. C. Moses, R. D. Silver, J. S. Flier, and M. C. Carey. Proc. Natl. Acad. Sci. USA 82:7419–7423 (1985).
J. W. Finkelstein, H. P. Roffwarg, R. M. Boyar, J. Kream, and L. Hellman. J. Clin. Endocrinol. Metab. 35:665–670 (1972).
K. Albertsson-Wikland and S. Rosberg. J. Clin. Endocrinol. Metab. 67:493–500 (1988).
R. G. Clark, J.-O. Jansson, O. Isaksson, and I. C. A. F. Robinson. J. Endocr. 104:53–61 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baldwin, P.A., Klingbeil, C.K., Grimm, C.J. et al. The Effect of Sodium Tauro-24,25-Dihydrofusidate on the Nasal Absorption of Human Growth Hormone in Three Animal Models. Pharm Res 7, 547–552 (1990). https://doi.org/10.1023/A:1015885204249
Issue Date:
DOI: https://doi.org/10.1023/A:1015885204249